Reporting owner · CIK 0002123284

Antz Christoph Rudiger

Visual SEC Form 4 history across 1 companies, 1 transactions and 1 filings.

CEOChief Executive OfficerVeraxa Biotech AG - Post de-SPAC
Open-market mix
Latest filingAug 31, 2026, 08:10 PM
Filings1Form 4 records
Buying$7.7K1 purchases
Selling$00 sales
Net value$7.7KBuys minus sells
Companies11 securities
Most recentAug 27, 2026buy

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for some of their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.

Monthly open-market activity

Reported purchase and sale transaction counts

Buys Sells
530-3-51Aug 26

Net value flow

Buys minus sells

Aug 26
$7.7K

Transaction texture

Ownership and ticket size

Average P/S size$7.7K
Median P/S size$7.7K
Direct1
Indirect0
Aug 27, 2026buy

Filing-only signals

Deterministic matches in this insider's history

CEO Buyrole1Director Buyrole1Direct Ownershipfiling-context1Large Holdings Increaseholdings1

Latest Form 4 facts

Quick context from source filings

Latest transaction

buy at Veraxa Biotech AG - Post de-SPAC on Aug 27, 2026 valued at $7,650.

Review SEC filing
Latest buy

buy at Veraxa Biotech AG - Post de-SPAC on Aug 27, 2026 valued at $7,650.

Review SEC filing
Latest sale

No open-market insider sale is available.

Associated companies

Visual map of known reporting history

VRXAVeraxa Biotech AG - Post de-SPAC1 transactions · latest Aug 31, 2026, 08:10 PM
TickerInsiderRoleTypeSharesValueCodeSignals90d returnFiledTrans date
VRXAAntz Christoph Rudiger
CEO
buy5.00k$765kP
CEO Buy Director Buy Direct Ownership+1
—08/3108/27

Antz Christoph Rudiger Insider Activity FAQ

SEC Form 4 context

Who is Antz Christoph Rudiger?

Antz Christoph Rudiger is a reporting owner in SEC Form 4 filings with reporting owner CIK 0002123284.

Which companies has Antz Christoph Rudiger reported transactions for?

Veraxa Biotech AG - Post de-SPAC

When was Antz Christoph Rudiger's latest insider buy?

buy at Veraxa Biotech AG - Post de-SPAC on Aug 27, 2026 valued at $7,650.

When was Antz Christoph Rudiger's latest insider sale?

No open-market insider sale is available for this period.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.